In an observational study, researchers report that the combination of casirivimab and imdevimab -- two monoclonal antibody treatments under Food and Drug Administration emergency use authorization -- keep high-risk patients out of the hospital when infected with mild to moderate COVID-19.
from Latest Science News -- ScienceDaily https://ift.tt/3gILcnA
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment